Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Physicians often fail to recommend genetic testing for breast cancer patients at high risk for mutations, according to a research letter published Feb…
From - Diagnostic Testing & Emerging Technologies
Investments in the diagnostics and tools (Dx/Tools) sector remained steady in 2016, according to Silicon Valley Bank's annual report…
From - Diagnostic Testing & Emerging Technologies
The case has been made repeatedly over the past few years regarding the need to increase physicians' genomics knowledge. Now, for the first time…
From - Diagnostic Testing & Emerging Technologies
Effective mid-February the U.S. Food and Drug Administration (FDA) is reclassifying antigen-based, rapid influenza virus antigen detection test systems (RIDTs) used…